{
  "docId": "019de076-1fa8-714d-830b-c99557c4e3f8",
  "docSlug": "94eecf41575130a8334503229ea21cd4",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 26 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 26,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a timeline-based process diagram to illustrate the randomization and treatment arms of the clinical trial.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-1fa8-714d-830b-c99557c4e3f8/18",
  "deckHref": "/decks/019de076-1fa8-714d-830b-c99557c4e3f8",
  "deckJsonHref": "/decks/019de076-1fa8-714d-830b-c99557c4e3f8.json",
  "deckAnchorHref": "/decks/019de076-1fa8-714d-830b-c99557c4e3f8#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.65,
        "x": 0.32,
        "y": 0.05
      },
      "kind": "diagram",
      "text": "Trial design timeline showing randomization at week 24 and treatment arms",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bfbe0fb6-02d5-42f5-9afe-a12ff3d0ef7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.65,
        "x": 0.32,
        "y": 0.75
      },
      "kind": "list",
      "text": "Mean HBsAg decline during lead-in phase was 1.6 log10 at week 24 of treatment; 93% of patients had HBsAg levels <100 IU/mL; 4 patients reached HBsAg levels <LLOQ",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "124b6b86-3765-49d0-83cc-e2f53bbb2364",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.32,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "POC: Proof of Concept *Data presented at EASL 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7027fcc9-ce22-4f52-94bd-13c8fb05540b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.5
      },
      "kind": "subtitle",
      "text": "Imdusiran in combination with ongoing NA therapy and short courses of Peg-IFNa-2a in cHBV patients",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a150ba64-60a6-48e1-b275-33e069a3d78a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "title",
      "text": "AB-729-201: Phase 2a POC Clinical Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad28b54f-56a4-4735-9c43-83b5eb401c0d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "962994c1-df42-407e-acae-ac1e1e0c165e",
      "evidence": "The slide uses a horizontal timeline to depict the clinical trial phases and randomization points.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}